Table 3.
Predictors of overall survival, univariate and multivariate analysis (Cox regression model)
| Univariate analysis | Multivariate analysis | |
|---|---|---|
| Variables | HR (95% confidence interval, p value) | HR (95% confidence interval, p value) |
| Age over 72y at COVID-19 diagnosis | 2.69 (1.76–4.09, p < 0.001) | 1.62 (0.87–3.00, p = 0.125) |
| Gender male vs. female | 1.80 (1.10–2.95, p = 0.019) | 0.91 (0.47–1.74, p = 0.769) |
| Obesity | 0.71 (0.43–1.17, p = 0.178) | 0.59 (0.31–1.12, p = 0.105) |
| Major comorbidities | 2.01 (1.20–3.35, p = 0.008) | 1.30 (0.62–2.72, p = 0.482) |
| Hypogammaglobulinemia | 1.38 (0.84–2.25, p = 0.208) | – |
| TP53 deletion/mutation present vs. absent | 1.72 (1.00–2.96, p = 0.050) | 1.29 (0.65–2.58, p = 0.469) |
| IGHV unmutated vs. mutated | 1.85 (1.13–3.03, p = 0.014) | 1.47 (0.80–2.71, p = 0.211) |
| Ever treated vs. "watch and wait" | 3.52 (2.03–6.12, p < 0.001) | 3.28 (1.26–8.58, p = 0.015) |
| Currently treated for CLL at COVID-19 diagnosis | 2.60 (1.73–3.92, p < 0.001) | 0.67 (0.14–3.07, p = 0.603) |
| Treatment with BTK inhibitor* | 2.02 (1.29–3.16, p = 0.002) | 2.59 (0.57–11.71, p = 0.215) |
| Chemoimmunotherapy* | 2.14 (1.27–3.63, p = 0.004) | 0.92 (0.23–3.62, p = 0.901) |
| Treatment with anti-CD20 monoclonal antibody* | 2.44 (1.54–3.86, p < 0.001) | 1.47 (0.22–9.77, p = 0.693) |
| Steroids for COVID-19 | 6.44 (3.62–11.45, p < 0.001) | 12.13 (4.71–31.24, p < 0.001) |
*at COVID-19 diagnosis, multivariable Cox model containing all predictors with P < .20 from the univariable models was constructed, with each predictor adjusted for all others in the model. Numbers marked in bold indicate statistically significant results